Bridgewater Advisors Inc. Boosts Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Bridgewater Advisors Inc. raised its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 13,017 shares of the medical device company’s stock after buying an additional 433 shares during the period. Bridgewater Advisors Inc.’s holdings in DexCom were worth $1,031,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Versant Capital Management Inc acquired a new stake in shares of DexCom during the fourth quarter worth $25,000. Riverview Trust Co lifted its position in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares during the period. RPg Family Wealth Advisory LLC purchased a new stake in DexCom during the 3rd quarter valued at about $57,000. Covestor Ltd increased its holdings in shares of DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after purchasing an additional 335 shares during the period. Finally, UMB Bank n.a. raised its stake in shares of DexCom by 82.4% in the fourth quarter. UMB Bank n.a. now owns 1,678 shares of the medical device company’s stock worth $130,000 after purchasing an additional 758 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.30% of the stock is owned by insiders.

DexCom Trading Down 0.5 %

DXCM opened at $84.38 on Monday. The stock has a market capitalization of $32.96 billion, a PE ratio of 50.53, a P/E/G ratio of 2.00 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The business’s 50 day moving average price is $78.17 and its 200 day moving average price is $77.75.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on DXCM shares. Oppenheimer reduced their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Wells Fargo & Company boosted their price objective on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price target for the company from $86.00 to $104.00 in a research report on Thursday. Finally, Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $99.29.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.